Ziwig Endotest® enables the diagnosis of endometriosis with a reliability of over 95 %[1,6]. Using a simple saliva sample, the expression pattern of 109 different micro-RNAs involved in the development of endometriosis is examined. Ziwig Endotest® uses the two cutting-edge technologies of high-throughput sequencing and artificial intelligence.

Intended use:
Ziwig Endotest® has been validated and approved for patients aged from 18 to 43 who exhibit symptoms that indicate endometriosis[9]:

- chronic pelvic pain
- +/- dysmenorrhea
- +/- deep dyspareunia
- +/- painful dysuria/miction
- +/- painful dyschezia/defecation
- +/- painful rectal bleeding or haematuria during menstruation
- +/- pain in the shoulder tip
- +/- infertility

Ziwig Endotest® may be useful in the following situations:
- Patients with suspected endometriosis following normal or inconclusive results of diagnostic imaging.
- Patients with persistent endometriosis symptoms despite medical treatment and normal or inconclusive results of diagnostic imaging.

Exclusions:
Endometrioma and endometriosis of the rectosigmoid, identified using ultrasound or an MRI scan.

Ziwig Endotest® requires a medical prescription. The saliva sample must be collected under the supervision of a medical specialist.

- The patient must be at least 18 years old and no older than 43 years old at the time the test is performed.
- The patient must not have any prior history of cancer or infection with the human immunodeficiency virus (HIV).
- The patient must not be pregnant at the time the test is performed.
- Ziwig Endotest® can be performed during hormone treatment.
- Ziwig Endotest® can be performed at any point in the cycle